Buy & Sell AST SpaceMobile Inc (ASTS) – AST SpaceMobile Inc Price Today
Aura AI Summary
Key Stats
- $31.63BMarket Cap
- MediaSector
- -39.11%3M Drawdown
- $31.59BEnterprise Value
- -Dividend Yield
- 27 daysTypical Hold Time
AST SpaceMobile Inc (ASTS) is currently valued at a market capitalization of $31.63B, with an enterprise value of $31.59B. Over the past 52 weeks, AST SpaceMobile Inc has traded between a low of $23.07 and a high of $122.09, highlighting its annual price range. Over the past three months, AST SpaceMobile Inc has recorded a drawdown of -39.11%, reflecting recent price volatility. On average, investors hold AST SpaceMobile Inc for approximately 27 days, indicating typical investor behavior on the platform.
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Most Recent News
CBAK Energy unveils advanced LFP cylindrical batteries boosting Southeast Asia's electric mobility.
CBAK Energy Technology showcased its innovative lithium-ion and sodium-ion cylindrical batteries designed for Southeast Asia's electric two- and three-wheelers at Autotech & Accessories 2026. Their batteries feature long life, high reliability, and s...

WeRide and Renault deploy autonomous Robobus at Roland-Garros for third year, expanding night service.
WeRide and Renault Group continue their partnership by operating the autonomous Robobus shuttle service at the Roland-Garros tennis tournament for the third consecutive year. The service runs a 2.8 km route connecting key points around the stadium, o...

Eli Lilly's gene therapy VERVE-102 cuts LDL cholesterol by up to 62% with lasting effects.
Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no seriou...
